As with other medicines in the incretin-based drug class, retatrutide is associated with a range of side effects, the majority of which relate to the gastrointestinal system
Because insurance plans vary and can change, it is best to contact your insurance provider for up-to-date coverage information
Cardiovascular outcome trials (including LEADER, SUSTAIN-6, REWIND, and SELECT) have demonstrated that certain GLP-1 receptor agonists reduce major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors
These approaches are common among doctors who specialize in medical weight management, and as such, medical record data can be studied to inform future guidelines and standardization about maintenance-phase dosing in particular
Just science-backed results
For patients experiencing GLP-1 digestion issues , consistency with daily routines-hydration, meals, and gentle movement-can improve digestion and prevent setbacks